期刊文献+

药物耐药性外排泵抑制剂的研究进展 被引量:9

Advance in efflux pump inhibitors for multidrug resistance
下载PDF
导出
摘要 外排泵抑制剂可以抑制耐药细菌和肿瘤细胞对进入胞体内药物的外排作用,提高对药物的敏感性。它在改善药物的药动学特性等方面也有广泛的作用。研制开发外排泵抑制剂,逆转现有药物的耐药性将是改善药物疗效的一种有效的治疗方法。简要阐述近年来外排泵抑制剂的研究进展。 Active efflux,one of chief resistant mechanisms of tumour cells and bacteria,can result in the resistance of tumour cells and bacteria to therapeutic agents,which is known to be one of the main reasons for the failure in clinical therapy.Efflux pump inhibitors not only reverse the active efflux of tumour cells and bacteria and recovery their sensitivity to therapeutic agents,but also improve their pharmacokinetic attributes such as enhancing oral bioavailability.Therefore,the development of efflux pump inhibitors is a promising approach to overcome the resistance of tumour cells and bacteria to therapeutic agents.The recent efflux pump inhibitors are summarized in this brief review.
机构地区 山东大学药学院
出处 《中国药物化学杂志》 CAS CSCD 2005年第3期188-192,共5页 Chinese Journal of Medicinal Chemistry
关键词 药物化学 构效关系 外排泵综述 外排泵抑制剂 多重耐药性 medicinal chemistry structure-activity relationships efflux pump review efflux pump inhibitors multidrug resistance
  • 相关文献

参考文献26

  • 1Varma MVS,Ashokraj Y,Dey CS,et al.P-glycoprotein inhibitors and their screening:a perspective from bioavailability enhancement[J].Pharm Res,2003,48(4):347-359.
  • 2Jeremy PB,Katherine AV,Susan H,et al.Evaluation of toremifen for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine[J].Cancer Chemother Pharmacol,2000,46(1):27-34.
  • 3Teodori E,Dei S,Quidu P,et al.Design,synthesis,and in vitro activity of catamphiphilic reversers of multidrug resistance:discovery of a selective,highly efficacious chemosensitizer with potency in the nanomolar range[J].J Med Chem,1999,42(10):1687-1697.
  • 4Loe DW,Oleschuk CJ,Deeley RG,et al.Structure-activity studies of verapamil analogs that modulate transport of leukotriene C4 and reduced glutathione by multidrug resistance protein MRP1[J].Biochem Biophy Res Commun,2000,275(3):795-803.
  • 5Advani R,Saba HI,Tallman MS,et al.Treatment of refractory and relapsed acute myelogeous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833(valspodar)[J].Blood,1999,93(3):787-795.
  • 6Seiden MV,Swenerton KD,Matulonis U,et al.A phase Ⅱ study of the MDR inhibitor biricodar(incel,VX-710)and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy[J].Gynecol Oncol,2002,86(3):302-310.
  • 7Nokihara H,Yano S,Nishioka Y,et al.A new quinoline derivative MS-209 resistance and inhibits multiorgen metastases by P-glycoprotain-expressing human small cell lung cancer cells[J].Cancer Res,2001,92(7):785-792.
  • 8Planting AS,Sonneveld P,van der Gaast A,et al.A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2005,55(1):91-99.
  • 9Gallo S,Atifi S,Mahamoud A,et al.Synthesis of aza mono,bi- and tricyclic compounds.Evaluation of their anti MDR activity[J].Eur J Med Chem,2003,38(1):19-26.
  • 10Sandler A,Gordon M,de Alwis DP,et al.A phaseⅠtrial of a potent P-glycoprotein inhibitor,zosuquidar trihydrochloride(LY335979),administered intravenously in combination with doxorubicin in patients with advanced malignancy[J].Clin Cancer Res,2004,10(10):3265-3272.

同被引文献59

引证文献9

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部